CC
APLS

Centiva Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Centiva Capital’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-65,475
Closed -$5.96M – 1704
2023
Q2 		$5.96M Buy
+65,475
New +$5.65M 0.13% 138

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Centiva Capital's APLS Position: Q3 2023 in Review

Centiva Capital sold out of Apellis Pharmaceuticals (APLS) in Q3 2023, closing a stake of 65,475 shares — an estimated $5.96M sold.

Centiva Capital first reported a position in APLS in Q2 2023 and held it in 1 quarter. The position peaked at $5.96M in Q2 2023. 256 funds tracked by Wall St. Rank hold APLS as of Q3 2023.

  • Centiva Capital reported no remaining Apellis Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Centiva Capital sold 65,475 Apellis Pharmaceuticals shares in Q3 2023, an estimated $5.96M.
  • Centiva Capital first reported a position in Apellis Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Centiva Capital's Apellis Pharmaceuticals position peaked at $5.96M in Q2 2023.
  • 256 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2023.

Based on Centiva Capital's 13F filing for Q3 2023, filed 14 Nov 2023.